H.C. Wainwright raises Enliven Therapeutics price target to $73
H.C. Wainwright raised its price target for Enliven Therapeutics (ELVN) to $73 from $65, maintaining a Buy rating. The stock is currently at $37.32, down 8.6% over the past week but up 142% year-to-date. The firm cited alignment with the FDA on the Phase 3 ENABLE-2 trial design for relcobatinib (ELVN-001) in chronic myeloid leukemia patients. Analysts expect positive trial results based on previous data. Other analysts also issued positive ratings and price targets for ELVN.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a higher price target may drive short-term buying pressure, but the ultimate catalyst remains the Phase 3 trial outcomes.
Market read
The target raise adds fresh bullish sentiment for ELVN, potentially influencing biotech sector sentiment.
What to watch
Potential competition from other CML treatments and the risk of trial delays could temper upside.
Background
Enliven Therapeutics (NASDAQ:ELVN) is a biotech developing relcobatinib for chronic myeloid leukemia. The article reports new analyst price targets and trial design details.
Ticker impact
H.C. Wainwright raised its price target on Enliven Therapeutics to $73, citing positive Phase 3 trial design and lower discount rate.
likely upward pressure as investors price in higher valuation and trial optimism
The new $73 target is a material increase from $65 and reflects fresh trial design news, which can attract buying interest.
Market effects
Positive signal for biotech firms developing CML therapies and for the broader oncology sector.
U.S. biotech market may see modest gains as the target raise influences peer valuations.
Limited to investors tracking U.S. listed biotech stocks.
Counterpoint
The trial is still early; investors may wait for actual Phase 3 data before committing.
Key entities
- companyEnliven Therapeutics
Biotech developing relcobatinib for CML.
- analyst_firmH.C. Wainwright
Raised price target to $73.
